SCRI Tissue Testing Registry

Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in
clinical research and correlative science. To this end, the SCRI Oncology Research
Consortium will collect written consent from patients allowing the use of their tumor tissue
sample(s) for testing/analysis at a future date. Future testing may include assays for newly
identified markers of potential prognostic and/or therapeutic value. These markers may be
specific to an individual cancer type, or they may be present more generally in cancer
and/or other conditions.

This study will consist of a registry of patients who have agreed to allow their tissue
sample(s) (even those taken prior to their participation in an SCRI-sponsored trial) to be
used by the SCRI Oncology Research Consortium at some point in the future for testing and
analysis of expression analysis and/or analysis of tumor markers. The registry will be
contained in an electronic database, and will be sorted by disease indication. (Note:
Patients will not be asked to return at a future date and have tissue samples collected;
rather, SCRI will have the authorization to obtain pre-existing samples).

Inclusion Criteria:

- Patients must be >= 18 years of age.

- Patients must be able to provide written informed consent.

Exclusion Criteria:

- Not Applicable